Ozempic

China is the great candy of pharmaceutical thinning. And there is a wild race for selling the new ozempic

by

Few would have guessed not so long that a pharmacist focused on the insulin segment would become a company with A higher value than Tesla. Novo Nordisk became the most valuable quoted company in Europe Thanks to the fashion product: Ozempic. This diabetes treatment spun by becoming the Miracle of weight loss that many needed, Despite its side effects. But there are situations that do not last forever and China is about to seize Ozempic tooth in a market with a lot of potential. And they have about twenty biosimilar copies calling the door. Challenging the reign. In recent days we have seen that something strange has happened with Ozempic. By mistake or for a failure in the calculations, Novo Nordisk carries years without paying protection rates of the Ozempic patent in Canada. It is a quota that serves to protect the compound on which the popular Ozempic and Wegovy drugs, the same pharmaceutical drugs. It is something that is allowing local companies to be Finally generic medications based on the peptide similar to LPG-1. It is about the hormone that “mimics” the semagglutide that allows this antidiabetic and thinning effect. The Chinese market rubs your hands. In China, something similar happens. The patents have a life time that allow those who have registered them with that competitive advantage, but after the established period, the ban opens. While in Europe and Japan this patent will expire in 2031, and in 2032 in the United States, the protection of the patent in China It will expire Next year, as we read in South China Morning Post. Lek Consulting is a consultant based in Boston and comments that “China is home to populations with the highest number of diabetic and overweight people, and has become a key battlefield for both global pharmaceutical giants and for local actors.” Montones competitors. According to the SCMP report, in China there are at least 20 biosimilar copies that will compete for this market share, which will generate absolute pressure in the prices of the semaglutida. “The panorama in China is expected to become even more competitive than in the developed markets, where the category of GLP-1 medicines is dominated by large multinational pharmaceuticals,” commented Helen Chen, global co -director of Medical Care and Life Sciences of Le.K. Currently, Novo Nordisk opera In China both with Ozempic and Wegovy, but Eli Lilly also operates in the Chinese market, the American company with a response to the drug that could enter the country thanks to the premises Innovent Biologics. In the summer last year, They announced An expansion plan of more than 200 million euros to expand a plant in Suzhou with which to meet demand in the Asian giant. But, in addition, there are several dozens of drugs that are in advanced phases of clinical trials in China and, as they comment from Le.K., some have potential to compete directly with Novo Nordisk and Eli Lilly products. A very fat cake. That there are so many interested parties is the most normal. China, by overwhelming population numbersit is a huge market for any product, but in this field, we are talking about the second largest pharmaceutical market in the world, with almost 150 million adults with diabetes. It is more than any other country and, according to the International Diabetes Federation, the estimate is that the figure increases to 168 by 2050. But also, in 2021 The Lancet Medical Magazine estimated that 402 million people over 25 years in continental China had obesity. By contextualizing, it is a figure that represents 38% of the population and that reflects the country’s life progress. In 1990, the figure was 15.8% and wait that reaches 61% in 2050. New generation. Grand View Research is an American consultant who wait That the GLP-1-based medication market triples its sales in China by 2030, from 1,430 million dollars last year to 4.7 billion. But of course, there are more competitors for Ozempic does not imply that Novo Nordisk is cross -arms. A few months ago, the Danish company announced that the results for Your new medicine, called CagrisemaThey were promising. In the essays, its new combination of Semaglutida and Cagrilintida It has shown a striking potential, with a medium weight loss of 15.7% in 68 weeks compared to 3.1% of the group that received placebo. In addition, they reached a development and manufacturing agreement of another compound known as UBT251 with a Chinese laboratory, United Biotechnology, which will be responsible for commercialization in China, Hong Kong, Macao and Taiwan. Everything based on miracles? It is evident that Novo Nordisk does not want to lose the train of the new generations of drugs that have exploited in popularity thanks to their status as miraculous compounds for weight loss. But not everything is needles, since Eli Lilly is already Testing pills with the same effects as the ‘Ozempicazo‘And more natural alternatives are being explored, such as diet, in the search for a “Natural Ozempic” Although, beyond the miracle, the closest thing to that “natural ozempic” is a balanced diet, exercise and good rest. The Holy Trinity of Healthy Lifeultimately. Images | Javier Quiroga, HAVEREDAS In Xataka | The Danish city paradox where the “formula” of Ozempic is manufactured. It is the epicenter of childhood obesity of the nation

Since his arrival, Zepbound was predestined to unseat Ozempic. The big question is why it is taking so long

by

In innovation, arriving first is a tremendous push when Develop a groundbreaking product. However, it is not a guarantee of success. This is a lesson that Danish pharmaceuticals Novo Nordisk is learning in their own meats. The last years have been marked by success the drugs of the GLP-1 family as Ozempic, Wegovy either Zepbound. The name refers to the peptide similar to glucagon-1 or LPG-1 (a hormone segregated in our body when we eat) since this type of formulas contain active compounds that “mimic” this hormone. In origin, drugs such as Ozempic or Zepbound were designed as diabetes treatment since one of the functions of the GLP-1 hormone It is to warn the pancreas of food entry to accelerate insulin production. However, the success of these treatments occurred due to a side effect also related to this hormone: and it is that the second of the messages transmitted by the LPG-1 is addressed to the brain, and it is the one that triggers the feeling of satiety. This is why agonist drugs of GLP-1 receptors also have a slimming effect. Companies that had compounds such as semaglutid New brands with which to market your compounds reorient to weight loss: Wegovy and Mounjaro. Throughout this process, the drugs of the Danish pharmacist, Ozempic and Wegovy, left with a kind of advantage, but there was a problem. The problem: the “recipe” of the American pharmaceuticals Lilly showed better results where these more treatments have highlighted, weight loss. The apparent reason is that just as the semaglutida is a simple agonist of the GLP-1 receptors, the tirzepatida is a double agonist of the GLP-1 receptors and of the receptors of the polypeptide gastric inhibitor or insulinotropic peptide dependent on glucose (GIP). If this were not enough, the magnitude of success reached an unexpected level, which had a serious involvement: Supply problems. This was not an exclusively economic but also health problem, we reconnected that before a product focused on weight loss, Ozempic was a diabetes treatment. A demand High and dissatisfied It is a great opportunity for the entry in play of new competitors, and this was precisely the panorama that the American pharmacist Lilly was found. A at odds Lilly launched Mounjaro in 2022 and success was vertiginous: the recipes shot and the new product seemed to quickly unseat their competitors. However, three years after launch it seems that the anticipated has not yet been Sorpasso. In fact, after a final stretch of 2024, some analysts wondered what was happening, why the success of Lilly’s formulas is postponing so much. However, In an article for Biospacethe consultants Gary Stibel and Riley McCarthy, of New England Consulting Group gave another key. For them the key to Ozempic’s persistence was in the marketing. In his article, Stibel and McCarthy indicate that Lilly attributed his difficulties when reaching the expected volume of sales to the high manufacturing costs and “fluctuating” levels of inventory in a high demand context. That is, that Lilly also managed to deal with the success of his own product. In the United States pharmaceuticals can announce more or less conventional medications that are only administered under medical prescription. According to these consultants, part of Ozempic’s success is due to these consumer -oriented campaigns. Although ultimately the choice of medication falls on the person in charge of signing the recipe, the patient’s weight can also be decisive. Regardless of campaigns of marketingit is difficult to overestimate the value of first such a lucrative market. Ozempic monopolized headlines and covers for months, and has become a few years in a kind of vulgarized brandthat is, a brand that has become an entire category of products. Something that in the short term can be a great advantage but long entails the erosion (even legal) of the brand itself. 2025 seems to draw a most hopeful panorama For the American pharmacist, but anticipating what will happen in the medium and long term is difficult for several reasons. Both pharmaceuticals continue to work with greater or lesser success in new formulas, double and even triple agonists that could unseat the products already settled. Laboratory results are difficult to predict and will depend in part with the future of these pharmacists. Another important factor is that we do not know the roof of this market. The calculations From the consulting firm Goldman Sachs they expect this roof will be reached at the beginning of the decade that comes, standing at about 120,000 million dollars around 2035. There is room for growth: according to the consultant the market volume in 2025 will be about 28,000 million dollars. This volume will have to be distributed with New formulaseven with generic alternativesthat could not take long to arrive after the threat that hits the Canadian patent of the Semaglutida. The expiration of the patents of these formulas will aggravate the need for the pharmaceuticals involved in introducing These new formulas that contribute something new to an increasingly competitive market. In Xataka | “Ozempic face”, “Ozempic language” and “Ozempic teeth”: the other very visible effect of consuming the medicine to lose weight Image | News Oresund

Generic medications have been trying to site Ozempic for years. And now they have found a shortcut in Canada

by

Something strange has happened with the patent that protects Ozempic In Canada. By mistake or by strategic decision, Novo Nordisk, the company responsible for developing the semaglutida, the compound on which the popular drug is based has been without paying the maintenance rates of this patent. An error of millions. The surprise jumped a few days ago. The chemist and expert disseminator in Pharmaceutical Industry Derek Lowe indicated Through an article in Science that the Danish pharmaceutical 370 dollars Canadians annual) that protects the compound on which drugs such as Ozempic and Wegovy are based. According to the Canada patent databasethe status of this patent is that of “expired and beyond the reversal period.” According to the Canadian Law, companies have a 12 -month grace period for claims and payment of late payments (another 150 Canadian dollars today). A period that would have already exceeded. Rubbing his hands. History began to reveal itself earlier this month. In an interview With the media specialized in pharmaceutical industry, Richard Saynor, CEO of Sandoz, talked about launching a generic medicine based on the peptide similar to glucagon 1 (LPG-1), the hormone to which the semaglutida to make its antidiabetic and slimming effect. As Lowe explains in his piece, the competition in the generic market can become “extremely beast.” Companies dedicated to this type of drugs seek as much as possible the patents, looking for failures that can invalidate them and thus be able to enter new markets. And today there are few markets as tempting as that of agonists of the GLP-1 hormone receptors such as Ozempic, Wegovy or Rybelsus. This family of drugs, oriented in its origin to treat diabetes, has achieved immense success for its slimming effect, triggering a whole revolution not only pharmaceutical, but also economic. A permeable border. An important detail mentioned by Saynor in its interview is that Canada is the second major semaglutidal market (after the United States). This would not be, speculate, because Canadians are great consumers of the drug, but is probably a consequence of the cross -border business. “There is clearly a dynamic, as with insulin, with business through the border,” Explains the director of Sandoz. “It will be interesting how this evolves,” he says. Evil of many … The expiration of the patent in Canada would not only affect Novo Nordisk but also could suppose a hard blow to its main competitor in the diabetes treatments and weight loss, the American Eli Lilly. The entrance into the market of a generic competitor would imply that the manufacturing company of Zepbound and Mounjaro. These drugs are based on the tirzepatida, a compound that acts as an analogue of the LPG-1 and also of another hormone called polypeptide gastric inhibitor or GIP. A mistake? An error? We began pointing out that patents are a fundamental pillar of the pharmaceutical industry which makes the doubt prevailing: why? It is difficult to know if everything is due to a simple error or a calculated strategy. “I never knew why this is sure that someone lost their job, but it doesn’t matter,” Saynor held in his interview. If it were a mistake, it would not be a mere mistake. According to Lowe explainsthe company showed in writing there by 2017 its reluctance to the payment of the maintenance rate of the Canadian patent of the Semaglutida. He boom Ozempic would not be given until years later, because perhaps the company was not able to anticipate success and considered the price of maintaining a patent in the North American country. In Xataka | In search of “natural ozempic”: what science knows about diets that simulate the effect of miracle medications Image | Rene Baker / Chemist4u

Psyllium went viral as a “natural alternative to Ozempic.” Reality is not so simple

by

Like any revolution, Ozempic came with promises and A hidden price. Then the side effects, the cost and the need for a medical prescription arrived. While its shadow is lengthened, an alternative option is born that does not need punctures through an millenary seed. The shell of a seed. What began as a traditional remedy in southern Asia today is a trend in Tiktok. More than 13,000 videos under the hashtag #psylliumhusk show how this fiber is incorporated recipes, Challenges and Tips for losing weightcalm appetite or improve digestion. But behind the viral phenomenon there is something much simpler: the Psyllium is the peel that surrounds the seeds of the ovata plantgo, a discreet but effective plant. Also known as Psilio, I know has used For years as soft laxative thanks to its ability to form mass and facilitate intestinal transit. The product can be consumed in dust, capsules or in its raw form, reminiscent of wood chips. Upon contact with water, this soluble fiber forms a thick gel. And it is precisely this viscosity that explains a good part of its benefits. Science behind. The secret of the Psyllium is how it reacts to water, since it absorbs and forms a thick gel. This process helps reduce appetite, improve intestinal transit and control cholesterol and blood sugar. In fact, an investigation He has confirmed ityou just have to consume between 10 and 15 grams daily to even reduce LDL cholesterol, the considered bad. Not everything is so simple. Although the enthusiasm in networks is understandable, experts ask for caution. First, for a security issue, since the Psyllium needs at least one liter of water for every 20 grams of fiber has pointed to The Guardian Lena Beal, spokesman for the Nutrition and Dietary Academy. The reason is none other than if it is not consumed without sufficient liquid, it can become a danger of suffocation or cause intestinal obstructions. It is not for everyone. It is not for everyone. Because it is natural, it does not mean that it is harmless. From Cleveland Clinic They do not recommend it in people with difficulties in swallowing, serious intestinal diseases (stenosis or crohn disease) or in cases of chronic digestive disorders. It is also advisable to take precautions if you are taking medication, since the fiber It can interfere. Natural Ozempic? Comparisons are always hateful, as the saying goes. The Psychlium shell does not alter the hormonal system as the GLP-1 agonists do. And although it can support weight loss, it does not do so in a powerful way or in all cases. More support. Because consuming more fiber is one of the most consistent recommendations of Modern nutritional science. In the end it is about incorporating improvements in the long -term diet, support that comes with a broader look on what it means to take care of yourself. Image | PGDP123 and Chemist4u Xataka | Ozempic and blindness, we have been on the track of an extremely rare adverse effect for months. Now the AEMPS has taken a step forward

Ozempic and blindness, we have been on the track of an extremely rare adverse effect for months. Now the AEMPS has taken a step forward

by

A few days ago the The United Kingdom warned on an unexpected effect associated with the use of Ozempic and treatments based on the same principle, the phenomenon of Ozempic Babies. Now the Spanish Agency for Medicines and Health Products (AEMPS) has also issued a statement but this time as a consequence of a very different effect. Adverse reaction. This week the AEMPS, the agency in charge of ensuring that the drugs meet the required standards, has issued A statement To warn of a very uncommon ocular adverse reaction “associated with treatments based on the semaglutida, the active compound of drugs such as Ozempic, Rybelsus or Wegovy. The notice occurs after the Committee for the Risk Assessment in Pharmacovigilance (PRAC) of the European Medication Agency (EMA) reviewed the risk of developing an ocular condition called Niana, which can cause loss of sudden vision. While the agency affects that the frequency of appearance of this type of eye problems is “very low”, it recommends that a sudden loss of vision is carried out an ophthanmological examination for Evaluate the possibility to interrupt the treatment. Noiana. Noiana is an acronym that refers to calls Previous ischemic optical neuropathiesNaion in English. These ailments are caused For the infarction of the optic nerve head. In other words, blood does not reach this eye region and a loss of vision occurs, which is typically fast but painless. It is an unknown and infrequent disease, not only in the context of those who follow a trailer treatment: its prevalence in the general population is approximately 10 cases per 100,000 inhabitants. A year on track. A year agoa study I found indications of the relationship between the treatments of Semaglutida and Niana. Indications such as those that gave rise to the evaluation by the Pract. The Committee reviewed clinical and preclinical essay data together with suspicion of adverse reactions, explains the AEMPS. This work resulted in the conclusion that trailer treatment can be associated with a risk of developing this disorder but indicate that with a very low frequency. The AEMPS speaks of “an increase in the risk of developing Niana of approximately double compared to people not exposed to this treatment. This corresponds to an additional case of NOIANA for every 10,000 patients treated with semagglutida for a year.” And what about the “other ozempic”? The AEMPS statement focuses on the drug -based drugs such as Ozempic, Rybelsus and Wegovy but does not indicate whether similar effects have been detected on similar treatments such as those based on the tirzepatida, such as Zepbound and Mounjaro. A medication with side effects. Like any drug, the semaglutida has a series of Contraindications and side effects. It should be remembered in this sense that the success of drugs such as Ozempic began when it was observed that this treatment against diabetes made those who followed it lost weight. In Xataka | “Ozempic face”, “Ozempic language” and “Ozempic teeth”: the other very visible effect of consuming the medicine to lose weight Image | Chemist4u / Amanda Dalbjörn

We have been seeing that Ozempic affects fertility. Now the United Kingdom has begun to take the “Ozempic Babies” seriously

by

Ozempic He began his career as a drug against diabetes but became one of the most popular medications worldwide when we realized that among its “side effects” was weight loss. Since then we have been detecting other possible effects, positive and negative but surely the most surprising of these is on its effects on fertility. Set deals with the phenomenon of the “Ozempic Babies” The United Kingdom warns. The authority responsible for regulating drugs and health products in the United Kingdom, MHRA (Medicines and Healthcare Products Regulatory Agency) warned a few days ago of a “new” side effect associated with the consumption of Ozempic, that of an increase in pregnancy probability. While this is the first time that the organism warns about the effect, the first news about this occurred More than a year ago. How it works. Ozempic is the brand with which Danish pharmaceuticals Novo Nordisk markets a diabetes treatment based on semaglutida. This compound also serves as a basis for Wegovyname under which the drug oriented to weight loss is marketed. To understand why the same compound can function as a treatment against diabetes and as a thinning we have to understand how it acts in our body. The semaglutida works as an agonist of the peptide receptors similar to glucagon-1 (LPG-1), that is, it works as an analogue of this key hormone in the digestive process. When we eat our body naturally secretes the GLP-1 hormone to transmit two messages. The first to the pancreas, so that it begins to segregate insulin with which to metabolize the sugars of the food. The second to the brain, so that this knows that we are satiated. Drugs like Zepbound and Mounjaro They act similarlyalthough the tirzepatida on which they are based works as a double analogue of LPG-1 and GIP hormones (gastric inhibitor polypeptide). Ozempic Babies. A little over a year ago, dozens of women in treatment with any of these medications They started informing of a strange phenomenon: They were becoming pregnant despite being considered infertile or despite resorting to contraceptives. This phenomenon was soon baptized as the “Ozempic Babies“,” Ozempic babies. “ How do you do it? Since the phenomenon began to document, many wondered how it was possible. There are two mechanisms (alternative or complementary) that can explain this phenomenon. The first has to do with contraceptives, specifically with oral contraceptives. One of Ozempic’s effects is that of slow down our digestionwhich in turn makes nutrients and other compounds absorb more slowly. In the preparation of an oral treatment, absorption speed is an important variable to take into account. Drugs such as contraceptives are designed for specific speeds, if these change too much, treatment can lose efficacy. He Another mechanism that could explain this phenomenon has to do with its slimming effect. As experts also highlight, there is an inverse relationship between obesity and overweight and fertility. It is possible, that by facilitating weight loss the drug is also contributing to increasing the probabilities of pregnancy. A double problem. The problem is double since it not only implies a greater probability of an unwanted pregnancy; also because this type of treatments They are contraindicated Not only for pregnant women, but also in those who seek to be. According to the recommendations, who wants to find a pregnancy should interrupt these treatments At least two months In advance to allow our body to return to normal and avoid unnecessary risks in a process as complex as gestation. Positive effects and negative effects. The “fever” by Ozempic and the drugs of its class began with a side effect: a medication aimed at treating diabetes made those who consumed it lose weight. The demand for these compounds has allowed us to find other possible Side effectspositive and negative, on which we have a greater or lesser degree of certainty. Possible adverse effects documented by the manufacturer itself can find problems such as aggravation of diabetic eye disease, potential allergic reactions and a variety of gastrointestinal symptoms, from nausea to constipation. However, since it also began to be used We have found indications on other possible effects. Some positives such as helping the fight against addictions or possible effects on renal health either cardiovascular. In the negative face we have also found indications of loss of hair and eye problems. In Xataka | “Ozempic face”, “Ozempic language” and “Ozempic teeth”: the other very visible effect of consuming the medicine to lose weight Image | Chemist4u / Camylla Battani

There is no miraculous recipe that gives us a “natural ozempic.” But science has some “tricks” that can help us

by

The popularity of the semaglutida (the active substance of the well -known Ozempic) and similar compounds, has led many to the search for alternatives that allow replicating Its effects without having to go through the pharmacy. It is not something to miss, like any other drug, Ozempic and similar medications have side effects, not to mention their cost or the fact that it can only be acquired with medical prescription. Having more alternatives within our reach can be tempting. The search for a “natural ozempic” however has more shadows than lights, more pseudoscience than science. That does not mean that the door is completely closed. One of the compounds to which often It has hung This label It is the Berber. Although some studies have detected pharmacological effects of this compound, we lack solid evidence today that proves to help us lose weight. What we do have is A series of risks associated with its consumption. Another regular candidate to serve as “natural ozempic” It’s green tea. Although this drink can give us some nutrients and help us stay hydrated, its effects on or on our glycemic levels They are limited at best. In An article for The conversationMary J. Scourboutakos, an expert from the University of Toront A “Ozempic of Nature”. The key to her is not in a compound that these foods can give us, but to focus on those who in one way or another stimulate the production of hormones that these treatments “imitate.” To understand it, we must remember how these compounds work. Semaglutida is an agonist of peptide receptors similar to type 1 glucagon (LPG-1), that is, it is a compound that functions as this key hormone for our digestive processes. The LPG-1 is a hormone that our stomach segregates when we eat with the aim of transmitting a double message. On the one hand, this hormone warns the pancreas that you should begin to segregate insulin to control blood sugar levels. These types of medications are, in origin, drugs against diabetes that stimulate insulin production for glycemic control in people who have trouble exercising this control. On the other hand, this peptide also sends a message to the brain: satiety. This is the reason why these compounds also make those who consume them lose weight, since they flatten hunger. Other drugs, such as Zepbound, They work similarly. The formula of the American Eli Lilly is based on the tirzepatida, which acts as an analogous not only of the LPG-1, but also of the GIP (polypeptide gastric inhibitor). Not only what, also how According to Explains Scourboutakosour diet can help stimulate the production of the GLP-1 hormone. He does not only through nutrients but also through our habits, when and how, in addition to what. With respect to nutrients, the expert highlights two, being the first, and perhaps the most important, fiber. The fiber is key Because it serves as food to our intestinal microbioma, and this in turn would be responsible for segregating compounds capable of stimulating hormone production. A study Posted in 2018 in the magazine Science He indicated that the fiber could help feed bacteria in charge of segregating short-chain fatty acids, which would be in this case those responsible for encouraging the secretion of the LPG-1. Recently, Another studyis published in Nature Microbiologyobtained similar results. The team responsible for this analysis detected that greater Presence of bacteria Vulgatus bacteroids and of its metabolite, vitamin B5 or pantotenic acid were able to activate the secretion of the peptide similar to type 1 glucagon. Returning to Scourboutakos articlethis highlights another key nutrient, monounsaturated fats, which we can find for example in the olive oil. Again, some studies support this notion, such as The published in 1999 In the magazine The American Journal of Clinical Nutritionwhich detected that olive oil stimulated better than butter the secretion of both LPG-1 and GIP. Regarding the “How”, ScourboTakos quotes for example A study In the magazine Diabetologyfrom which he concludes that consuming the most protein foods before the richest in carbohydrates (such as eating a fish dish and then one of rice) would give rise to a greater secretion of LPG-1. Other relevant factors mentioned by Scourboutakos include the time we consume food and even if we chew or consume in a liquefied form. Our diet affects our health and our well -being in very diverse ways. It may seem anti -limitic, but the closest thing to a “natural ozempic” we have is A varied diet, rich in fibers And in fats such as olive oil, whose positive properties have been well known for a long time. A diet of this type may not be able to cure diseases, but it is a necessary complement to many treatments and is an important preventive tool when avoiding problems for the future. In Xataka | Ozempic is supposed to increase the risk of erectile dysfunction. Thousands of people think exactly the opposite Image | Chemist4u / She Olsson

The “Ozempic effect” that is filling the mirrors with unknown faces

by

Thanks to Ozempic, many people have managed to fulfill a goal that had been chasing for years: losing weight faster. What was not expected is that it came with a collateral effect that was not on the prospect: an alien face. In the mirror there is another person. Fallen cheeks, loss of volume, sagging … and no, it is not natural aging. In social networks it has been baptized as “face Ozempic ”, a consequence of accelerated success in weight loss. According to Cleveland Clinicthese effects are not directly caused by the medication, but by the rapid loss of facial fat that accompanies weight loss. The trend. The conversation has gained strength especially after the testimonies of celebrities who have decided to talk about the physical changes they have experienced after using this type of medicines. One of the most popular voices has been that of Sharon Osbourne, British presenter, who has recognized having lost more than 15 kilos with Ozempic, but not without consequences. “I wouldn’t use it again. I look very thin and older, I regret it,” has declared In an interview with The Daily Mail. On the other hand, in social networks, many people are showing change with pride. On platforms like Tiktok, images of the before and afterhighlighting the physical transformation achieved with the use of Ozempic and similar medications. Science behind. From the medical point of view, the explanation is simple: if you lose very fast fat, you also lose it on your face. And not all the skin returns to its place. As detailed by Dr. Nyla Raja, Dermatologist with Clinic in Mayfair, In statements to the Evening Standard“When the thinning process is so accelerated, the skin does not have time to fall, which leads to sagging and a more aging appearance.” This loss of support in key areas such as cheekbones or jaw can cause the face to look more tired or aged than expected. It is not irreversible. Although the effects can be worrisome, there are solutions. Some dermatologists and nutritionists have agreed that the best way to avoid these consequences is to plan a gradual weight loss. According to Forbes has collectedmaintaining a rhythm of moderate weight loss, following a feed rich in protein and collagen, and practicing strength training can help preserve the facial structure. In some cases, aesthetic treatments such as radiofrequency, dermal fillings or even facial lifting are also resorted to correct the offalter. But… There are more effects. However, other unexpected ones are added to this phenomenon. According to The Independentthere are other secondary symptoms that are increasingly being documented. One of the most striking is “Ozempic language”, which is caused by oral dryness, which generates an alteration in taste. For its part, like has reported the same mediumDr. Tim Bradstock-Smith has pointed out that some patients experience “dry mouth, dental hypersensitivity and loss of volume on lips and cheeks, which compromises both aesthetics and oral health.” Besides, I know They have reported cases Blurred vision and, in rare situations, loss of vision associated with the use of semaglutida. The debate is no longer limited to the medical field. Ozempic, like other medicines to lose weight, has become a mirror of collective priorities: a culture of immediacy where the ideal body seems to be an injection of distance. But it is also true that, for many people, represents a real opportunity of recovering health, taking control over your weight and improving your quality of life. Reducing this conversation to aesthetic changes would be to simplify a deeply personal decision. Behind each treatment there are different stories, emotions and contexts. We live in a society every time more crossed by obsessions and trends that are born – and they are amplified – on social networks, where the ideal body is repeated with Filters and algorithms. At that cross, the direction that takes health, self -esteem and beauty is quite complex and dangerous. Image | Unspash and Instagram Xataka | Losing weight without losing muscle is the great challenge of drugs such as Ozempic. A protein keeps the key to face it

Losing weight without losing muscle is the great challenge of drugs such as Ozempic. A protein keeps the key to face it

by

It is usual for us to often get news about hopeful scientific advances made in mice. These experiments always leave a question in the air, if the discovery can be applicable to humans. This does not always happen, but sometimes MITCH Silence the expression of a simple protein in our muscles can lead to weight loss and, more, more, It can allow us to lose weight Without putting our muscle mass at risk. The protein in question is called Mtch2 (Mithochondrial Carrier Homolog 2), but has been nicknamed “Mitch” by those who study the compound and its effects. The last analysis of this protein and its associated gene has observed that its “erased” in human cells causes in these lower efficiency Energy What is perhaps more important, this silenced causes cells to stop using carbohydrates as a priority energy source and in place they preferably use body fat. Different fuels. The cells of our body need energy and billions of years of evolution have given rise to a series of biological mechanisms that allow us to maintain a calorie reserve that allow us to feed these cells in times of greater shortage. These mechanisms imply that our cells can resort to different fuels according to the situation. While the carbohydrates we consume and the fats that we use as a reserve are the main fuel Ozempic. From mitones to mitochondria. According to Explain the responsible teamthe new study has its bases in a previous experiment conducted with mice that observed in the rodents an “improvement” in their body composition in the form of “protection” against obesity and the development of more muscle fibers. This accompanied by greater consumption of greater oxygen consumption and an increase in resistance. The results were promising but left the team with a doubt, if it would be possible to “inoculate” the body against obesity by silencing the expression of a protein without this negatively affecting muscle mass. To look for an answer, the team went on to focus on the role of the mitochondría, the organelle in charge of providing energy to the cell. The key is in the fact that the “mitch” protein plays an important role in the merger of the mitochondria, a fusion capable of increasing the efficiency of these organelles. By silencing protein, organelles would lose the ability to resort to this fusion which also implies less efficiency and thereby a greater need to consume energy resources of our body. It only remained to prove if this was also true in human cells. Less efficiency, more consumption. They thus verified that by silencing the protein in human cells, the “mitochondrial network” was undone and, as expected, energy efficiency fell. This left the cell in a “permanent state of energy deprivation.” And what is more, the team also found that this led to the cells to prioritize the use of fats as a primary energy source, instead of other possible sources such as carbohydrates. “After erasing Mitch, we examined, every few hours, the effect that it had in more than 100 substances that take part in the metabolism of human cells,” pointed in a press release Sabita Chourasia, co -author of the study. “We saw an increase in breathing, the process in which the cell produces energy from nutrients, such as carbohydrates and fats. This explains the increase in muscle resistance of previous experiments in mice.” The details of the study were published In an article In the magazine Journal embo. An intermediate step. The study takes an important step in the long process between the first results in animal models and the design of a treatment for weight loss based on what was learned. In following studies, the team intends to elucidate new aspects about Mitch’s role in the accumulation of fat in the body. The fact that women usually have higher levels of this protein can help researchers discover if Mitch is also responsible for the differentiation of fatty cells. In Xataka | We are increasingly clear that our microbiome is key to our health. Our protein sources can also alter it Image | Weizmann Institute of Science

Ozempic has made thousands of people lose weight brutally. Then they have put their closet funds for sale

by

Novo Nordisk, the Ozempic manufacturer, has just presented the results of the first quarter and the data are impressive: we talk about 3,891 million euros, 14% more than last year. And, of course, that He has shot the price of the company. The most interesting, however, is why. And the answer is very simple: the treatments against obesity have risen 67%. It is what allows us to intuit that the Ozempic revolution (and the rest of the GLP-1 agonists go far beyond what we might think. So much so that he is putting up legs The second -hand market. Something is changing. In mid -2024, second -hand sales platforms began to see how the clothes offered in their systems changed. In the previous two years, large -scale women’s clothing ads had grown surprisingly: “A 103% increase in 3xl size ads, 80% in 4xl size and 73% in 5xl size”. Not only that, Poshmark analyzed the ads and discovered “a 78% increase in the new ads that mention ‘weight loss’ in the title or description.” Dressed Collective, specialized in second -hand sale of high quality products, has also detected a similar phenomenon and Goodwillfinds, which reverts donated clothing, says they are increasingly donated. Vinted He has also noticed. How do we know that all this has to do with Ozempic? We can’t be sure, it’s true. But, as they point out in Fortune, one in eight Americans already USA SEMAGLUTIDA OR ANOTHER GLP-1 agonist and the trend has been growing very closely to how the use of these medications grew. And, whatever it is, it is an issue that everyone begins to intuit that is serious. In fact, there are more and more resale programs of the brands themselves. Given these market changes, brands such as Levi’s, Patagonia and Carhartt Wip have begun to mount their own stores that allow them to also be present in this “second life” of their products. After all, As they point out in Vogue Business“The resale has been one of the only retail trade engines in recent years.” In fact, the market has been bent since 2021. However, not all the mountain is oregano. The problem is evident: as thousands of people lose weight significantly and They decide to purge their cabinetsthe stocks of second -hand stores are unbalanced: there is a lot of big clothes to sell and few people who want to buy it. That is, if analysts are right, we are going to A great readjustment of the fashion we produce, sell and buy. In a world pregnant with data and more data, it may seem curious that the first to realize have been Second -hand platformsbut little by that we think it is so predictable that it scares. Above all, To luxury brands. Image | YAP In Xataka | XL models: When you are harassed by your body in real life and influencer admired on Instagram

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.